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Abstract:  Biologics have enjoyed tremendous success as products in high income countries of the world.  
However the high cost of these products today prevent their use in low income countries and with the notable 
exception of palivizumab there has been little commercial interest in developing biologics for infectious diseases 
that are prevalent in these geographies.  Recent advances in the study of HIV, malaria, pertussis and Ebola 
highlight the potential of monoclonal antibodies (mAb) for prevention or treatment of these diseases.  The 
evolution of the industrialized CHO process over the past 30 years to satisfy market demands for mAbs is 
remarkable.  The need to meet high product quality standards and provide for reliable supply dominated design 
considerations of this process over process economics in the context of high margin products in the market 
today.  Innovation in bioprocessing to lower the production cost and ease scalability will be needed to enable 
potential lifesaving mAb products of tomorrow for the treatment of infectious diseases to reach people in those 
geographies most in need.   
 
